Table of Contents Table of Contents
Previous Page  712 / 812 Next Page
Information
Show Menu
Previous Page 712 / 812 Next Page
Page Background

S708

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2108

EV1124

Does clinical change always means the

same? Comparison of different

perspectives

S. Egger

, G.

Weniger , S. Prinz , S. Vetter , M. Müller

University Hospital for Psychiatry Zurich, ZIP, Rheinau, Zurich,

Switzerland

Corresponding author.

Introduction

In psychiatric practice, the assessment of change

frompre- to post-treatment is a key approach for monitoring treat-

ment effects and for the prediction of treatment outcomes. The

Health of the Nation Outcome Scales (HoNOS) as a clinician-rated

measure and the Brief Symptom Inventory (BSI) as a self-report

measure are tools (that are) often incorporated in outcome mon-

itoring. Their usefulness, however, has been questioned by two

important issues: their psychometric properties and their lack of

concordance.

Aims and objectives

The aimof the study is to evaluate the respon-

siveness of HoNOS and BSI as well as their interactions to predict

clinical meaningful change according to the Global Clinical Impres-

sion (CGI) as quasi-gold standard for treatment outcome.

Methods

A consecutive sample of patients admitted to a Swiss

psychiatric hospital for either alcohol use disorders, schizophrenic

psychoses, mood disorders, anxiety and somatoform disorders, or

personality disorders was assessed with Brief Symptom Inventory

(BSI) at admission anddischarge. TheHoNOS and the CGI were rated

by the responsible clinicians at admission and discharge. Ordinal

logistic regressions will be conducted using the CGI categories as

ordered categorical outcome. HoNOS and BSI scores as well as their

interaction terms will be used as independent variables.

Results and conclusion

Complete data of admission and discharge

is available fromapproximately 600 cases. Graphical presentations

will illustrate the resulting associations.

Keywords

Clinical Global Impression; Health of the Nation

Outcome Scales; Brief Symptom Inventory; Outcome monitoring;

Ordinal regression

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2109

EV1125

Descriptive study of the treatment of

delusional disorder. Survey study

DELIRANDA

B. Girela Serrano

1 ,

, L. Aguado Bailón

2

, P. Calvo Rivera

2

,

J.E. Mu˜noz Negro

2

, J. Cervilla Ballesteros

2

1

Hospital Santa Ana Motril, Psiquiatría, Motril, Granada, Spain

2

Hospital Universitario San Cecilio Granada, Psiquiatría, Granada,

Spain

Corresponding author.

Introduction

We currently lack clinical guidelines for the treat-

ment of Delusional Disorder (DD) F-22, the low prevalence of the

disease coupled with no awareness of illness and poor adherence

to prescribed treatment make it difficult to study. The limited evi-

dence available for the treatment is based mainly on clinical series.

Objectives

This study evaluates the knowledge and preferences

in the treatment of the DD, in order to improve clinical practice and

gain information of the DD to conduct clinical studies of effective-

ness of the different treatments.

Material and methods

A self-administered survey was con-

ducted on a sample of 80 psychiatrists proceeding on a wide

array of mental health care services. Participants provided socio-

demographic data and information about clinical details, together

with their opinions regarding the, epidemiological aspects, clini-

cal management, diagnosis and therapy. Descriptive statistics were

subsequently calculated with SPSS.

Results

Most of our sample’s of Psychiatrists estimated that the

DD prevalence was higher than the one previously established.

Ninety-three percent of the sample considered the SGAs as the

first treatment option in DD, being Aripiprazol 20.7%, Risperidone

17.4% and Paliperidone 15% the first line treatment chosen by our

Psychiatrists.

Conclusions and proposals

There is an increasing gap between the

old standard DD treatment and the clinical practice of Andalusian

Psychiatrists, for this reason we emphasize the need of implement-

ing clinical trials and effectiveness clinical studies.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2110

EV1126

Psychiatrists’ opinion on treatment

adherence in Delusional Disorder

B. Girela Serrano

1 ,

, L. Aguado Bailón

2

, P. Calvo

2

,

J.E. Mu˜noz Negro

2

, J. Cervilla Ballesteros

2

1

Hospital Santa Ana Motril, Psiquiatría, Motril, Granada, Spain

2

Hospital Universitario San Cecilio, Psiquiatría, Granada, Spain

Corresponding author.

Introduction

Delusional Disorder (DD) F22 is a disease with low

prevalence, probably underdiagnosed by clinical specialists due to

the high level of functionality, low awareness of disease, low dete-

rioration of patients and poor adherence to prescribed treatment.

Adherence to treatment is considered to be one of the major diffi-

culties that stand in the way of the treatment of DD. The present

paper assessed psychiatrists ´opinion of the adherence to treatment

of patients with DD.

Material and methods

A self-administered survey was conducted

on a sample of psychiatrists proceeding on a wide array of mental

health care services. Participants provided their opinions regarding

adherence to treatment. Descriptive statistics were subsequently

calculated with SPSS.

Results

In the opinion of our participants none of the patients

have an active compliance of the treatment, 36% consider that the

participation is partial or passive. It is also estimated that 57.5%

reject the treatment but not totally and 6.5% believe that rejection

is absolute.

Conclusions

Literature informs of the association of poor adher-

ence to treatment and little or no improvement of patients,

suggesting the need to address the lack of compliance and adher-

ence to treatment as a crucial aspect to improve the prognosis of

DD. To address this problem Long Acting Injections (LAIs) of Atypi-

cal Antipsychotics are postulated to be a plausible solution as a good

treatment strategy. In order to improve the clinical practice in DD

and obtain information for further effectiveness we emphasize the

need of implementing clinical studies.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2111